OPDIVO SC
As listed in the register: OPDIVO SC
120 mg · solution
- Prescription only
- Cancer treatments and immune-system medicines
- Active substance
- Nivolumab
- Made by
- Bristol-Myers Squibb Canada
- Source
- Official label
Quoted from the official source. Not yet reviewed by Mediclarum — the leaflet in your pack is authoritative.
What it is for
Mediclarum has not yet retrieved and stored the official label for this product, so none of its text is shown here. Open the official leaflet
How it works
From the US prescribing label for the same active substance (OPDIVO). It describes the substance, not this exact product.
Binding of the PD-1 ligands, PD-L1 and PD-L2, to the PD-1 receptor found on T cells, inhibits T-cell proliferation and cytokine production.
Upregulation of PD-1 ligands occurs in some tumors and signaling through this pathway can contribute to inhibition of active T-cell immune surveillance of tumors.
Quoted from the prescribing label, sections “Mechanism of Action” and “Pharmacokinetics”. DailyMed · 2026-08-12
Safety of the active substance
From the US prescribing label for the same active substance (OPDIVO). It describes the substance, not this exact product.
Most common adverse reactions (incidence ≥20%) in patients were:.
Quoted from the US prescribing label for the same active substance. Your own pack’s leaflet is the authority for your product. DailyMed
Same active substance, strength and form in other countries
Matched on active substance, strength and kind of form only. This is not a statement that the products are equivalent or interchangeable: other ingredients, release and approved uses can differ — ask a pharmacist before swapping.
Medicine passport: one printable page to show a pharmacist abroad
United StatesNo exact match for this strength and form
European UnionNo exact match for this strength and form
SpainNo exact match for this strength and form
FranceNo exact match for this strength and form
NetherlandsNo exact match for this strength and form
SwitzerlandNo exact match for this strength and form
Details
| Made by | Bristol-Myers Squibb Canada |
|---|---|
| Active substance | Nivolumab |
| Used in | Cancer treatments and immune-system medicines |
| Strength | 120 mg |
| Form | solution |
| Classification | L01FF01 · Cancer treatments and immune-system medicines |
| Route | subcutaneous |
| Dispensing (as stated by the register) | PRESCRIPTION · SCHEDULE D |
| Status | Approved |
| Marketed | No — authorised but not currently marketed, according to the register |
| DIN | 02566931 |
| DPD drug code | 106940 |
Source: Drug Product Database · 2026-09-30 · not reviewed by a clinician
Contains information licensed under the Open Government Licence – Canada. Reuse terms: Open Government Licence – Canada.
Other strengths and forms
2 products are sold under this name. Grouped by form; a number on a strength means several companies make it.
- solution2 products
120 mg2
120 mg · 2 companies
- Bristol-Myers Squibb Canada · this page
- Bristol-Myers Squibb Canada
Same active substance
These contain the same substance. That does not mean one can replace another — ask a pharmacist.